Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Risperidone
Drug: PF-02545920
Drug: Placebo

First Posted Date: 2010-08-04

Last Posted Date: 2018-05-22

Lead Sponsor: Pfizer

Target Recruit Count: 259

Registration Number: NCT01175135

Locations: 🇩🇪
Zentralinstitut fuer Seelische Gesundheit, Mannheim, Germany
🇺🇦
Kyiv City Psychoneurological Hospital #2, Kyiv, Ukraine
🇺🇦
Kyiv City Clinical Psychoneurological Hospital #1, Kyiv, Ukraine

and more 40 locations

To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-04995274

First Posted Date: 2010-08-02

Last Posted Date: 2011-06-01

Lead Sponsor: Pfizer

Target Recruit Count: 8

Registration Number: NCT01173757

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 0.1 mg PF-04995274
Drug: 1.0 mg PF-04995274
Drug: 1 mg PF-04995274
Drug: 10 mg PF-04995274
Drug: 15 mg PF-04995274

First Posted Date: 2010-07-26

Last Posted Date: 2011-01-20

Lead Sponsor: Pfizer

Target Recruit Count: 60

Registration Number: NCT01169714

Locations: 🇺🇸
Pfizer Investigational Site, Overland Park, Kansas, United States

A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: crizotinib

First Posted Date: 2010-07-23

Last Posted Date: 2011-10-24

Lead Sponsor: Pfizer

Target Recruit Count: 14

Registration Number: NCT01168934

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

Pharmacokinetics And Tolerability Of Subcutaneous Administration Of PF 04236921 In Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-04236921

First Posted Date: 2010-07-21

Last Posted Date: 2010-11-23

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT01166555

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

A Clinical Study Evaluating The Safety And Tolerability Of PF-04427429 In Healthy Adult Volunteers. The Pharmacokinetics And Pharmacodynamics Of PF-04427429 Will Also Be Investigated

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: PF-04427429

First Posted Date: 2010-07-20

Last Posted Date: 2012-02-22

Lead Sponsor: Pfizer

Target Recruit Count: 21

Registration Number: NCT01165723

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-05186462
Drug: PF-05089771
Drug: PF-05150122
Drug: PF-05241328

First Posted Date: 2010-07-20

Last Posted Date: 2010-08-24

Lead Sponsor: Pfizer

Target Recruit Count: 40

Registration Number: NCT01165736

Locations: 🇬🇧
Pfizer Investigational Site, Edinburgh, United Kingdom

A Single Dose Study Of PF-04620110 In Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-04620110

First Posted Date: 2010-07-20

Last Posted Date: 2010-08-20

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT01166217

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia

Phase 1

Withdrawn

Conditions: Hypercholesterolemia
Dyslipidemia

Interventions: Biological: 1 mg/kg every 2 weeks
Biological: 2 mg/kg every 4 weeks
Biological: 4 mg/kg every 4 weeks
Biological: 8 mg/kg every 8 weeks
Biological: 12 mg/kg every 8 weeks
Biological: Placebo
Biological: 4 mg/kg every 8 weeks

First Posted Date: 2010-07-16

Last Posted Date: 2015-04-23

Lead Sponsor: Pfizer

Registration Number: NCT01163838

Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tasocitinib plus Methotrexate
Drug: Tofacitinib plus placebo methotrexate
Drug: Placebo tofacitinib plus Methotrexate

First Posted Date: 2010-07-16

Last Posted Date: 2015-04-22

Lead Sponsor: Pfizer

Target Recruit Count: 109

Registration Number: NCT01164579

Locations: 🇲🇽
Hospital Angeles Mocel, Mexico D.F., Mexico
🇨🇿
Nemocnice na Frantisku s poliklinikou, Praha 1, Czech Republic
🇵🇱
Nzoz "Nasz Lekarz", Torun, Poland

and more 35 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy